GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » Receivables Turnover

InMed Pharmaceuticals (InMed Pharmaceuticals) Receivables Turnover : 4.04 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. InMed Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $1.17 Mil. InMed Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2024 was $0.29 Mil. Hence, InMed Pharmaceuticals's Receivables Turnover for the three months ended in Mar. 2024 was 4.04.


InMed Pharmaceuticals Receivables Turnover Historical Data

The historical data trend for InMed Pharmaceuticals's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Receivables Turnover Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 21.78 23.77

InMed Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.21 10.75 4.23 4.60 4.04

Competitive Comparison of InMed Pharmaceuticals's Receivables Turnover

For the Biotechnology subindustry, InMed Pharmaceuticals's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Receivables Turnover falls into.



InMed Pharmaceuticals Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

InMed Pharmaceuticals's Receivables Turnover for the fiscal year that ended in Jun. 2023 is calculated as

Receivables Turnover (A: Jun. 2023 )
=Revenue / Average Total Inventories
=Revenue (A: Jun. 2023 ) / ((Accounts Receivable (A: Jun. 2022 ) + Accounts Receivable (A: Jun. 2023 )) / count )
=4.136 / ((0.088 + 0.26) / 2 )
=4.136 / 0.174
=23.77

InMed Pharmaceuticals's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

Receivables Turnover (Q: Mar. 2024 )
=Revenue / Average Total Inventories
=Revenue (Q: Mar. 2024 ) / ((Accounts Receivable (Q: Dec. 2023 ) + Accounts Receivable (Q: Mar. 2024 )) / count )
=1.173 / ((0.373 + 0.208) / 2 )
=1.173 / 0.2905
=4.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InMed Pharmaceuticals  (NAS:INM) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.


InMed Pharmaceuticals Receivables Turnover Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Executives
Jonathan Tegge officer: Interim CFO 217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li officer: VP, Accounting and Controller 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond director 3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric A Adams director, officer: President & CEO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Brenda Edwards officer: Interim CFO 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove director 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill officer: CFO C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson officer: SVP & GM of BayMedica LLC 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler director 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner director 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu officer: Sr. VP, Pre-Clinical Res/Dev C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Michael Woudenberg officer: VP, Chem/Manufacturing/Control C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Mancini Alexandra Diane Janet officer: Sr VP, Clinical Reg Affairs C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4

InMed Pharmaceuticals (InMed Pharmaceuticals) Headlines